Protected environment - prophylactic antibiotic program for malignant sarcomas: randomized trial during remission...

Area of Science:

• Oncology
• Infectious Disease Control
• Clinical Pharmacology

Background:

• Malignant sarcomas are aggressive cancers requiring intensive chemotherapy.
• Chemotherapy regimens like CYVADIC can lead to significant immunosuppression and infection risk.
• Optimizing supportive care is crucial for improving outcomes in sarcoma patients.

Purpose of the Study:

• To evaluate the impact of protected environment-prophylactic antibiotic (PEPA) on infection rates and clinical outcomes in sarcoma patients undergoing chemotherapy.
• To assess the feasibility of escalating chemotherapy doses within the PEPA protocol.
• To determine if PEPA influences response rates, duration of response, and overall survival.

Main Methods:

• Fifty-one patients with malignant sarcomas were randomized to receive three courses of CYVADIC chemotherapy.
• The control group received standard care, while the experimental group received protected environment-prophylactic antibiotic (PEPA).
• Response rates, infection frequency, duration of response, survival, and chemotherapy dose escalation were assessed.

Main Results:

• The PEPA group experienced significantly lower infection rates compared to the control group.
• While response rates were similar (71% vs. 67%), PEPA patients had a substantially longer median survival (84 weeks vs. 58 weeks).
• Chemotherapy dose escalation was more frequent in the PEPA group, correlating with higher complete remission and lower fatality rates.

Conclusions:

• Protected environment-prophylactic antibiotic (PEPA) is effective in reducing infections during intensive sarcoma chemotherapy.
• PEPA facilitates chemotherapy dose escalation, leading to improved complete remission rates and reduced mortality.
• Implementing PEPA in sarcoma treatment protocols can significantly enhance patient survival and overall outcomes.